Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of HP-5120 in neuropathic low back pain
jRCT2031260552Phase 2Not yet recruiting
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lumbodynia (LBP) and Neuralgia comparing HP-5120 group with Placebo group (2 arms). Primary endpoint: Change in NRS. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
HP-5120
03
Conditions
lumbodynia (LBP)Neuralgia
Beyond the preview
Go deeper on jRCT2031260552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260552.